Jon P. Stonehouse - Jan 4, 2022 Form 4/A - Amendment Insider Report for BELLICUM PHARMACEUTICALS, INC (BLCM)

Role
Director
Signature
/s/ Richard A. Fair, Attorney-in-Fact
Stock symbol
BLCM
Transactions as of
Jan 4, 2022
Transactions value $
$0
Form type
4/A - Amendment
Date filed
9/1/2022, 04:39 PM
Date Of Original Report
Jan 6, 2022
Previous filing
Dec 16, 2021
Next filing
Jan 13, 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BLCM Common Stock Options Exercise $0 +21.1K +2105.4% $0.00 22.1K Jan 4, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BLCM Restricted Stock Units Options Exercise $0 +21.1K $0.00 21.1K Jan 4, 2022 Common Stock 21.1K Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This amendment is being filed to correct the typographical error in the amount of converted RSUs on the original Form 4 filed with the SEC on January 6, 2022.
F2 Each Restricted Stock Unit (the "RSU") represents a contingent right to receive one share of BLCM common stock.
F3 The RSUs were granted on January 4, 2021 and vested in full upon the one year anniversary.